Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs
NCT00392275 · View on ClinicalTrials.gov ↗
Study Summary
Based on previous results with eyes without filtering blebs, the aqueous concentrations of ofloxacin and levofloxacin will exceed the concentration of ciprofloxacin after either topical or topical plus oral administration.
Conditions Studied
Interventions
- DRUG Ofloxacin 0.3%
- DRUG Ciprofloxacin 0.3%
- DRUG Levofloxacin 0.5%
- DRUG Ofloxacin 400mg
- DRUG Ciprofloxacin 400mg
Study Locations (3)
Indiana
- Indiana University Hospital — Indianapolis
- Richard L Rodeboush VA Medical Center — Indianapolis
- Wishard Memorial Hospital — Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2002-11 |
| Est. Completion | 2006-05 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00392275
The ClinicalTrials.gov registry entry for NCT00392275 describes a study currently listed as completed. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University School of Medicine, which has 16 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 5 interventions — of which Ofloxacin 0.3% is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00392275 reports 3 study locations spanning 1 distinct geographic area — top geographies include Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00392275 about?
NCT00392275 is a clinical study titled "Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs". Based on previous results with eyes without filtering blebs, the aqueous concentrations of ofloxacin and levofloxacin will exceed the concentration of ciprofloxacin after either topical or topical plus oral administration.
What is the current status of trial NCT00392275?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2002-11. Estimated completion is 2006-05.
What conditions does trial NCT00392275 study?
This clinical trial studies the following conditions: Cataract. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00392275?
The interventions under investigation include: Ofloxacin 0.3% (DRUG), Ciprofloxacin 0.3% (DRUG), Levofloxacin 0.5% (DRUG), Ofloxacin 400mg (DRUG), Ciprofloxacin 400mg (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00392275?
This trial is sponsored by Indiana University School of Medicine, which has 16 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00392275 being conducted?
This trial has 3 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.